Intralesional 5-Fluorouracil in the Treatment of Lower Leg Squamous Cell Carcinoma

November 2018 | Volume 17 | Issue 11 | Features | 1241 | Copyright © November 2018


Morgan Mackey DO,a Adam Shahsavari DO,b V. Thomas Mackey DOa

aAdvanced Desert Dermatology, Peoria, AZ and the Osteopathic Postdoctoral Training Institution (OPTI) at Midwestern University, Glendale, AZ bLarkin Palm Springs Community Hospital, Hialeah, FL

REFERENCES

  1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069-1080.
  2. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146:283- 287.
  3. Lauren Metterle, Christopher Nelson, Nishit Patel. Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): A review. J Am Acad Dermatol. 2016:74:552-557.
  4. Margolis DJ, Berlin JA, Strom BL. Risk Factors Associated with the Failure of a Venous Leg Ulcer to Heal. Arch Dermatol. 1999;135:920–926.
  5. Joslyn S. Kirby, Christopher J. Miller. Intralesional chemotherapy for nonmelanoma skin cancer: A practical review. J Am Acad Dermatol. 2010;63:689-702.
  6. B.H. Miller, J.S. Shavin, A. Cognetta, et al. Nonsurgical treatment of basal cell carcinomas with intralesional fluorouracil/epinephrine injectable gel. J Am Acad Dermatol.1997;36:72-77.
  7. Laurie M. Good, Misha D. Miller, Whitney A. High. Intralesional agents in the management of cutaneous malignancy: A review. J Am Acad Dermatol. 2010;64:413-422.
  8. Nicole M. Annest, Marta J. VanBeek, Christopher J. Arpey, et al. Intralesional Methotrexate treatment for keratoacanthoma tumors: A retrospective study and review of the literature. J Am Acad Dermatol. 2007;56:989-993.
  9. Vishwas Parekh, John T. Seykora. Cutaneous Squamous Cell Carcinoma. Clin Lab Med. 2017;37:503-525.

AUTHOR CORRESPONDENCE

Morgan Mackey D.O. mmackeydo@gmail.com
Close Menu